Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2015 by BrainsGate
Information provided by (Responsible Party):
BrainsGate Identifier:
First received: January 19, 2009
Last updated: September 2, 2015
Last verified: September 2015
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in patients with an acute ischemic stroke in the anterior circulation initiated within 24 hours from stroke onset.

Condition Intervention Phase
Ischemic Stroke
Device: The Ischemic Stroke System
Device: Sham control
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double Blind, Sham Control, Parallel Arm Trial to Assess Effectiveness and Safety of the Ischemic Stroke System ISS, as an Adjunct to Standard of Care in Subjects With Acute Ischemic Stroke

Further study details as provided by BrainsGate:

Primary Outcome Measures:
  • Distribution of patients across the ordinal modified Rankin scale (mRS) [ Time Frame: 90 days ] [ Designated as safety issue: No ]

    The primary effectiveness endpoint will be the modified Rankin Scale (mRS) evaluated by the site on Day 90±7.

    The statistical analysis of the primary effectiveness endpoint will be: Sliding Dichotomous mRS.

Secondary Outcome Measures:
  • Sliding Dichotomous mRS for subjects with aphasia at baseline [ Time Frame: 90 days ] [ Designated as safety issue: No ]
  • Binary NIHSS (success for score ≤ 1 or for ≥ 9-point improvement versus baseline) [ Time Frame: 90 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 800
Study Start Date: January 2009
Estimated Study Completion Date: November 2017
Estimated Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Active Stimulation
Implantation and ISS Stimulation during five consecutive days & Standard of Care
Device: The Ischemic Stroke System
SPG stimulation and standard of care
Sham Comparator: Sham Stimulation
Sham Implantation and Sham Stimulation during five consecutive days & Standard of Care
Device: Sham control
Sham stimulation and standard of care

Detailed Description:

A multi-center, multinational, randomized, double blind, sham control, adjunctive to Standard of Care, parallel arm study and will include ongoing DSMB review of accumulated safety data.


Since the treatment should be initiated within 24 hours from stroke onset, the screening window is limited and all procedures should be performed within this window.Subjects with Acute Ischemic Stroke will be screened upon arrival to the hospital. Since the treatment should be initiated between 8 and 24 hours from stroke onset, the screening window is limited and all procedures should be performed as soon as possible. All screened patients will be identified by patient number and will sign the informed consent prior to any study procedure initiation.

Period 1: Day 1-5

: Day 1- Eligible subjects will be randomized in a 1:1 (ISS Stimulation: Sham Control) ratio:

  • Group 1: Implantation and ISS Stimulation during five consecutive days & Standard of Care
  • Group 2: Sham Implantation and Sham Stimulation during five consecutive days & Standard of Care Subjects will be transferred to the implantation procedure facility and the implantation/sham implantation will be performed by a trained physician.

Following implantation, stimulation/sham stimulation will be delivered. Day 2-4 ISS / Sham Stimulation will be repeated during the following four consecutive days by trained personnel within 18-26 hours from preceding stimulation.

Day 5 / Day of Discharge. Following the last ISS /Sham Stimulation, explantation will be performed and the patients will be evaluated for safety and effectiveness.

Subjects will continue with Standard of Care as needed and will be released from the hospital upon investigator's judgment.

Period 2: Day of Discharge - 89±7 days During this period both groups (ISS Stimulation and Sham Control) will be treated according to Standard of Care either at the hospital, rehabilitation center or at home.

Scheduled visits will be performed on day 30±7 and day 60 ±7, which will include safety and effectiveness assessments.

Final Visit Day 90±7 days: The final visit will be performed at the study site and will include safety and effectiveness evaluations.

Patients will be contacted by study personnel via telephone on Day 180±7 and on Day 360±7 in order to assess their quality of life status.


Ages Eligible for Study:   40 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age: Between 40 years and 80 years for male and 85 for female subjects
  2. Clinical diagnosis of an acute ischemic stroke in the Carotid, Middle or Anterior Cerebral Artery territories
  3. Imaging findings demonstrating signs of ischemia in the anterior circulation, consistent with the clinical diagnosis
  4. Baseline NIHSS ≥ 7 and ≤ 18 within 2 hours prior to implantation.
  5. Ability to initiate treatment within 8- 24 hours from stroke onset
  6. Signed informed consent from patient him/herself or legally authorized representative if applicable

Exclusion Criteria:

  1. Intracranial hemorrhage or hemorrhagic transformation
  2. Massive stroke
  3. Acute ischemic stroke in the posterior circulation
  4. Minor stroke
  5. Treated with IV-tPA ,IA-tPA or neurothrombectomy devices for the current stroke
  6. Previous stroke in the last 6 months or pre-existing disability
  7. Patients with bleeding propensity or any condition in the oral cavity that prevents implantation
  8. Clinical signs and symptoms or imaging evidence of bilateral stroke.
  9. Treated with IV-tPA ,IA-tPA or neurothrombectomy devices for the current stroke.
  10. Known cerebral arteriovenous malformation, cerebral aneurysm.
  11. Clinical suspicion of septic embolus.
  12. Uncontrolled hypertension (systolic >185 mmHg and/or diastolic >110 mmHg)
  13. Serious systemic infection.
  14. Women known to be pregnant or having a positive or indeterminate pregnancy test.
  15. Patients with other implanted neural stimulator/ electronic devices (pacemakers).
  16. Life expectancy < 1 year from causes other than stroke.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00826059

Contact: Eyal Ozeri 972 4 637 7774

United States, Florida
Intercoastal Medical Group Recruiting
Sarasota, Florida, United States, 34232
United States, Illinois
Central DuPage Hospital Recruiting
Winfield, Illinois, United States, 60190
United States, Massachusetts
UMASS Medical Center Withdrawn
Worcester, Massachusetts, United States, 01655
United States, North Carolina
Guilford Neurologic Associates Recruiting
Greensboro, North Carolina, United States, 27401
United States, Ohio
ProMedica Toledo Hospital Recruiting
Toledo, Ohio, United States, 43606
United States, South Carolina
Palmetto Health Richland Recruiting
Columbia, South Carolina, United States, 29203
United States, Tennessee
Erlanger Stroke Center Recruiting
Chattanooga, Tennessee, United States, 37404
Erlangen University Clinic Recruiting
Erlangen, Germany
Essen University Clinic Recruiting
Essen, Germany
Heidelberg University Clinic Recruiting
Heidelberg, Germany
Leipzig University Clinic Recruiting
Leipzig, Germany
Hospital Vall d'Hebron Recruiting
Barcelona, Spain
Sponsors and Collaborators
Study Director: Eyal Shay BrainsGate
  More Information

No publications provided

Responsible Party: BrainsGate Identifier: NCT00826059     History of Changes
Other Study ID Numbers: CLP1000500
Study First Received: January 19, 2009
Last Updated: September 2, 2015
Health Authority: United States: Food and Drug Administration
Germany: Ethics Commission
Spain: Agencia Española de Medicamentos y Productos Sanitarios

Keywords provided by BrainsGate:
acute ischemic stroke
randomized clinical trial

Additional relevant MeSH terms:
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Nervous System Diseases
Pathologic Processes
Vascular Diseases processed this record on November 27, 2015